Moberg Pharma
Research Moberg Pharma (MOB.ST) on Bullrun: market cap SEK 518.99M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMOB.ST
- ExchangeXSTO
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 518.99M
- Financial periodQ1 2026
- RevenueSEK 4.92M
- Net income-SEK 1.26M
- Free cash flow-SEK 8.04M
- Gross margin66.2%
Valuation Snapshot
latest market cap is SEK 518.99M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 13.54M | -SEK 27.24M | -SEK 60.68M | 56.7% | -0.58 | SEK 230.25M | SEK 2.55M | SEK 665.22M |
| FY2024 | SEK 9.81M | -SEK 255.11M | n/a | 64.4% | -6.74 | SEK 293.29M | n/a | SEK 686.82M |
| FY2023 | SEK 0 | -SEK 21.09M | n/a | n/a | -1.33 | SEK 60.56M | n/a | SEK 610.73M |
| FY2022 | SEK 207.00K | -SEK 15.71M | n/a | 100.0% | -2.07 | SEK 125.55M | n/a | SEK 533.58M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | SEK 518.99M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Moberg Pharma
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Moberg Pharma's market cap?
Moberg Pharma's market capitalization is SEK 518.99M.
What does Moberg Pharma do?
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.